The FDA is weighing requiring DTC TV ads to carry a toll-free number for adverse events reports and is surveying 1,600 consumers to find out what they think, AP reported.
DTC foe Dingell pushed to head health subcommittee
Supporters of Rep. John Dingell (D-MI), arguably the leading critic of consumer advertising in Congress, are pushing him to head a powerful health subcommittee, The Hill has reported.
CCC to launch medical education and advertising certification
The Center for Communication Compliance (CCC) has launched new certification programs for healthcare advertising and promotional medical education professionals.
A federal appeals court has overturned a lower court’s injunction of New Hampshire’s ban on commercial provision of prescription data, arguing that such restrictions do not constitute an abridgment of free speech.
Congress to investigate FDA’s medical device approval process
Reps. John Dingell (D-MI) and Bart Stupak (D-MI) have launched an investigation into the FDA’s process for reviewing medical devices, following an accusatory letter from FDA scientists and physicians.
The healthcare plan unveiled by Sen. Max Baucus yesterday would require disclosure of “gifts and other transfers of value” from drug and device manufacturers to healthcare professionals.
FDA public relations contract scrutinized by Congress
Senators Mike Enzi (R-WY) and Tom Coburn (R-OK) are requesting information on the FDA’s contract process, specifically with respect to a no-bid public relations campaign contract.
DoJ recovered $694.5 million from drug and device manufacturers in 2008
The Department of Justice (DoJ) recovered a total of $694.5 million in settlements from a device manufacturer and two pharmaceutical companies during FY 2008.
MedPac to Congress: Make pharmas report all samples to HHS
MedPac, the congressional advisory commission on Medicare, has endorsed stringent transparency rules for drug, device and biologics manufacturers, including detailed reporting on drug samples with the aim of facilitating targeted counter-detailing.
Congressional pharma foes square off over committee gig
Fight! Fight! Two leading congressional critics of the pharma industry—Rep. Henry Waxman (D-CA) and John Dingell (D-MI)—are at odds over a committee chairmanship.